New combo aims to shrink tough skin cancer before surgery
NCT ID NCT07501104
First seen Apr 13, 2026 · Last updated May 24, 2026 · Updated 4 times
Summary
This study tests whether giving three drugs (pucotenlimab, lenvatinib, and temozolomide) before surgery can improve outcomes for people with a rare type of skin cancer called acral melanoma. About 30 adults with stage IIB or III melanoma that can be removed will receive the drugs for 3 cycles, then have surgery. After surgery, those whose cancer didn't respond well may continue one drug for a year. The main goal is to see how many patients have a major response in the tumor.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA (SKIN CANCER) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.